ArticleFrontiers in pharmacology2017
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.
Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of Anti-Calcitonin Gene-Related Peptide for Migraines: A Systematic Review with Meta-Analysis of Randomized Clinical Trials.International journal of molecular sciences · 2019Pooled it
- Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, in Healthy Chinese Participants.Clinical pharmacology in drug development · 2025Trial
- Trial
- Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.JAMA neurology · 2018Trial
- Waning light, waxing pain: The lunar cycle's association with migraine headache occurrence.Headache · 2026Article
- Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptide.Communications medicine · 2025Article
- Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling.Antibodies (Basel, Switzerland) · 2024Article
- Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Clinical Pharmacokinetics.European journal of drug metabolism and pharmacokinetics · 2024Review
- Anti-CGRP antibody galcanezumab modifies the function of the trigeminovascular nocisensor complex in the rat.The journal of headache and pain · 2024Article
- Eptinezumab for the preventive treatment of episodic and chronic migraine: a narrative review.Frontiers in neurology · 2024Review
- Revisiting dose-finding of monoclonal antibodies in migraine.The journal of headache and pain · 2023Article
- Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine.Neurology international · 2023Article
- Baseline demographics and disease characteristics of patients with episodic or chronic cluster headache: data from two phase 3 randomized clinical trials in Europe and North America.Frontiers in neurology · 2023Article
- Galcanezumab modulates Capsaicin-induced C-fiber reactivity.Cephalalgia : an international journal of headache · 2022Article
- The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review.Therapeutic advances in neurological disorders · 2022Article
- Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.The journal of headache and pain · 2021Observational
- Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?Pharmaceuticals (Basel, Switzerland) · 2021Review
- The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache.Drugs · 2020Review
- Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine.Pharmacology research & perspectives · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.